Amgen’s Response to ICER’s Background and Draft Scoping Document: “Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis: Effectiveness and Value”

Sep 14, 2016

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory condition that can lead to structural joint damage, disability, quality of life and functional impairments, as well as productivity losses both in the short and long terms.1-8 The short and long term effects of RA are not limited to patients; they extend to the patients’ families, employers, and society as a whole. Over the last several decades, sustained investments in research and development have translated into numerous innovative treatments available to patients.

Read More ›

Arthritis Foundation Comments to ICER on Rheumatoid Arthritis and Psoriatic Arthritis | By: Sandie Preiss

Aug 1, 2016

On behalf of the more than 50 million adults and 300,000 children in the United States with doctor-diagnosed arthritis, the Arthritis Foundation appreciates the opportunity to provide comments to ICER on the selected topic of rheumatoid arthritis (RA). RA is a complex chronic disease that can be difficult to treat, and people who suffer from the disease require regular, ongoing professional care.

Read More ›

Scoping Document for ICER Review of Drugs for Rheumatoid Arthritis Posted for Public Comment

Aug 1, 2016

–Document will inform development of report for public deliberation by the Midwest CEPAC–

August 1, 2016 – The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document that will inform a report on drug therapies for rheumatoid arthritis. The document will be open to public comment for three weeks.

Read More ›